Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation

Bone Marrow Transplantation

Volumn 21, Issue 10, 1998, Pages 1005-1010

  Colby, C ^a   McAfee, S L ^a   Finkelstein, D M ^b   Spitzer, T R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Autologous peripheral blood stem cell transplantation; Granulocyte colony stimulating factor (G CSF); Hematopoietic recovery

Indexed keywords

ANTIBIOTIC AGENT; CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FEVER; HOSPITALIZATION; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TIME;

EID: 0031776595     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701203     Document Type: Article

References (20)

1. Sheridan JD, Wolfe M, Lusk J et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891-895.
2. Taylor KMcD, Jagannath S, Spitzer G et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989; 7: 1791-1799.
3. Spitzer G, Adkins DR, Spencer V et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661-670.
4. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323-1327.
5. Madero L, Munoz A, Diaz de Heredia A et al. G-CSF after autologous bone marrow transplantation for malignant diseases in children. Bone Marrow Transplant 1995; 15: 349-351.
6. Stahal RA, Jost LM, Cernay T et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994; 12: 1931-1938.
7. Soutre E, Quing W, Penelaud PE. Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation. Eur J Cancer 1996; 32A: 1162-1165.
8. McQuaker IG, Hunter AE, Pacey S et al. Low-dose filgrastim significantly enhances neutrophil recovery following atologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451-457.
9. Linch DC, Scarffe H, Proctor S. Randomized vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993; 11: 307-311.
10. Lord BI, Bronchud MH, Ownes S et al. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 1989; 86: 9499-9502.
11. Fabuabm I, Kletter Y, Bleiberg I et al. Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation. Exp Hematol 1991; 19: 868-873.
12. Tarella C, Benedetti G, Caracciolo D et al. Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. Br J Haematol 1995; 91: 535-543.
13. Ottinger HD, Beelen DW, Scheulen B et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775-2779.
14. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing for ordered categorical data. Biometrics 1984; 40: 819-825.
15. Moreau P, Tortorec BM, Legros L et al. Administration of granulocyte-stimulating factor from day 7 after bone marrow transplantation: effects on neutropenia and duration of hospitalization. Nouv Rev Fr Hematol 1994; 36: 455-458.
16. Khwaja A, Mills W, Leveridge AH et al. Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT. Bone Marrow Transplant 1993; 11: 479-482.
17. Dunlop DJ, Fitzsimons EJ, McMurray A et al. Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue. Br J Cancer 1994; 70: 943-945.
18. Vey N, Molnar S, Faucher C et al. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery. Bone Marrow Transplant 1994; 14: 779-782.
19. Torres G, Jimenez MA, Alvarez MA et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. Ann Hematol 1995; 71: 65-70.
20. Cetkovsky P, Koxa V, Jindra P et al. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation. Bone Marrow Transplant 1997; 20: 639-641.